Lyra touts pos­i­tive topline PhII da­ta for chron­ic rhi­nos­i­nusi­tis drug

Lyra Ther­a­peu­tics de­buted pos­i­tive topline da­ta this morn­ing for one of its lead pro­grams, LYR-220, which aims to treat chron­ic rhi­nos­i­nusi­tis in pa­tients who still …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER